ACADIA PHARMACEUTICALS INC. INDEMNITY AGREEMENTIndemnity Agreement • February 27th, 2004 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) is made and entered into as of , 2004 by and between ACADIA PHARMACEUTICALS INC., a Delaware corporation (the “Company”), and (“Agent”).
Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4),And License Agreement • February 27th, 2004 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations
COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT By and Among ACADIA PHARMACEUTICALS INC., ALLERGAN, INC. and ALLERGAN SALES, LLCAnd License Agreement • February 27th, 2004 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations • California
THIS COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Agreement”), entered into as of March 27, 2003 (the “Effective Date”) by and among ACADIA PHARMACEUTICALS INC., a Delaware corporation (“ACADIA”), with offices at 3911 Sorrento Valley Blvd., San Diego, California 92121, and Allergan, Inc., a Delaware corporation, and Allergan Sales, LLC, a Delaware limited liability company (collectively “Allergan”), both having offices at 2525 Dupont Drive, Irvine, California 92612.
ContractAcadia Pharmaceuticals Inc • February 27th, 2004 • Pharmaceutical preparations • California
THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THIS WARRANT.
AMENDED AND RESTATED STOCKHOLDERS AGREEMENTStockholders Agreement • February 27th, 2004 • Acadia Pharmaceuticals Inc • Pharmaceutical preparations
THIS AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”) is entered into as of March 27, 2003, by and among ACADIA PHARMACEUTICALS INC., a Delaware corporation (the “Company”), those individuals and entities identified on the signature page hereof as the “Existing Institutional Stockholders” (individually, each an “Existing Institutional Stockholder” and collectively, the “Existing Institutional Stockholders”), MARK R. BRANN (the “Founding Stockholder”) and the entities identified on the signature page hereof as the “New Institutional Stockholders” (individually, each a “New Institutional Stockholder” and collectively, the “New Institutional Stockholders”). Each of the Existing Institutional Stockholders and New Institutional Stockholders are sometimes referred to herein as an “Institutional Stockholder” or collectively as “Institutional Stockholders.” Each of the Institutional Stockholders and the Founding Stockholder are sometimes referred to as “Stockholder” and are colle
MANAGING DIRECTOR CONTRACTAcadia Pharmaceuticals Inc • February 27th, 2004 • Pharmaceutical preparations
